Zydus Launches PEPAIR OPEP Device for Chronic Respiratory Conditions

The launch comes amid rising respiratory disease burden in the country, with over 9 million patients estimated to be living with chronic respiratory conditions, according to the company.

Zydus Lifesciences announced the launch of PEPAIR, an Oscillating Positive Expiratory Pressure (OPEP) device designed to support mucus clearance and improve breathing in patients with chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis.

The company described PEPAIR as India’s first affordable OPEP device. The launch comes amid rising respiratory disease burden in the country, with over 9 million patients estimated to be living with chronic respiratory conditions, according to the company.

Chronic mucus hypersecretion remains a common challenge among these patients, often requiring consistent airway clearance as part of daily management. OPEP therapy uses a handheld device that creates pressure and vibrations during exhalation, helping to loosen mucus, open airways, and facilitate its removal.

PEPAIR is a drug-free, handheld device intended for routine respiratory care. It is being introduced under an agreement with AeroDel Technology Innovations, an Indian medical device company focused on inhalation-based drug delivery and pulmonary rehabilitation solutions.

Commenting on the launch, Sharvil Patel, Managing Director of Zydus Lifesciences, said, “With PEPAIR, India’s first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma, and bronchiectasis.”

Respiratory illnesses in India have been increasing, driven by factors including persistent air pollution, climate-related changes in allergens and ozone levels, rapid urbanization, and delayed diagnosis of chronic lung diseases. COPD, asthma, and bronchiectasis contribute significantly to morbidity and healthcare utilization across the country.

The device is positioned as a non-pharmacological intervention aimed at improving airway clearance as part of routine respiratory management. Further details on pricing and distribution were not disclosed.

Stay tuned for more such updates on Digital Health News